These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 26364181

  • 1. Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas.
    Piludu F, Marzi S, Pace A, Villani V, Fabi A, Carapella CM, Terrenato I, Antenucci A, Vidiri A.
    Neuroradiology; 2015 Dec; 57(12):1269-80. PubMed ID: 26364181
    [Abstract] [Full Text] [Related]

  • 2. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.
    Ellingson BM, Kim HJ, Woodworth DC, Pope WB, Cloughesy JN, Harris RJ, Lai A, Nghiemphu PL, Cloughesy TF.
    Radiology; 2014 Apr; 271(1):200-10. PubMed ID: 24475840
    [Abstract] [Full Text] [Related]

  • 3. Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation.
    Vidiri A, Pace A, Fabi A, Maschio M, Latagliata GM, Anelli V, Piludu F, Carapella CM, Giovinazzo G, Marzi S.
    J Exp Clin Cancer Res; 2012 Apr 11; 31(1):33. PubMed ID: 22494770
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab.
    Kickingereder P, Wiestler B, Graf M, Heiland S, Schlemmer HP, Wick W, Wick A, Bendszus M, Radbruch A.
    J Neurooncol; 2015 Jan 11; 121(2):373-80. PubMed ID: 25359396
    [Abstract] [Full Text] [Related]

  • 5. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
    Hilario A, Sepulveda JM, Hernandez-Lain A, Salvador E, Koren L, Manneh R, Ruano Y, Perez-Nuñez A, Lagares A, Ramos A.
    Clin Transl Oncol; 2017 Jan 11; 19(1):51-57. PubMed ID: 27026567
    [Abstract] [Full Text] [Related]

  • 6. Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility.
    Kim HS, Goh MJ, Kim N, Choi CG, Kim SJ, Kim JH.
    Radiology; 2014 Dec 11; 273(3):831-43. PubMed ID: 24885857
    [Abstract] [Full Text] [Related]

  • 7. Quantitative T1 and T2 mapping in recurrent glioblastomas under bevacizumab: earlier detection of tumor progression compared to conventional MRI.
    Lescher S, Jurcoane A, Veit A, Bähr O, Deichmann R, Hattingen E.
    Neuroradiology; 2015 Jan 11; 57(1):11-20. PubMed ID: 25287076
    [Abstract] [Full Text] [Related]

  • 8. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.
    Artzi M, Bokstein F, Blumenthal DT, Aizenstein O, Liberman G, Corn BW, Ben Bashat D.
    Eur J Radiol; 2014 Jul 11; 83(7):1250-1256. PubMed ID: 24809637
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
    Kickingereder P, Brugnara G, Hansen MB, Nowosielski M, Pflüger I, Schell M, Isensee F, Foltyn M, Neuberger U, Kessler T, Sahm F, Wick A, Heiland S, Weller M, Platten M, von Deimling A, Maier-Hein KH, Østergaard L, van den Bent MJ, Gorlia T, Wick W, Bendszus M.
    Radiology; 2020 Oct 11; 297(1):164-175. PubMed ID: 32720870
    [Abstract] [Full Text] [Related]

  • 12. Dynamic Contrast-Enhanced Perfusion MRI and Diffusion-Weighted Imaging in Grading of Gliomas.
    Arevalo-Perez J, Peck KK, Young RJ, Holodny AI, Karimi S, Lyo JK.
    J Neuroimaging; 2015 Oct 11; 25(5):792-8. PubMed ID: 25867683
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma.
    Kickingereder P, Radbruch A, Burth S, Wick A, Heiland S, Schlemmer HP, Wick W, Bendszus M, Bonekamp D.
    Radiology; 2016 May 11; 279(2):542-52. PubMed ID: 26579564
    [Abstract] [Full Text] [Related]

  • 15. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
    Kickingereder P, Wiestler B, Burth S, Wick A, Nowosielski M, Heiland S, Schlemmer HP, Wick W, Bendszus M, Radbruch A.
    Neuro Oncol; 2015 Aug 11; 17(8):1139-47. PubMed ID: 25754089
    [Abstract] [Full Text] [Related]

  • 16. Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.
    Molina D, Pérez-Beteta J, Martínez-González A, Sepúlveda JM, Peralta S, Gil-Gil MJ, Reynes G, Herrero A, De Las Peñas R, Luque R, Capellades J, Balaña C, Pérez-García VM.
    PLoS One; 2016 Aug 11; 11(8):e0161484. PubMed ID: 27557121
    [Abstract] [Full Text] [Related]

  • 17. The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET).
    Field KM, Phal PM, Fitt G, Goh C, Nowak AK, Rosenthal MA, Simes J, Barnes EH, Sawkins K, Cher LM, Hovey EJ, Wheeler H.
    Cancer; 2017 Sep 15; 123(18):3576-3582. PubMed ID: 28678383
    [Abstract] [Full Text] [Related]

  • 18. Comparison of T1 mapping and fixed T1 method for dynamic contrast-enhanced MRI perfusion in brain gliomas.
    Conte GM, Altabella L, Castellano A, Cuccarini V, Bizzi A, Grimaldi M, Costa A, Caulo M, Falini A, Anzalone N.
    Eur Radiol; 2019 Jul 15; 29(7):3467-3479. PubMed ID: 30972545
    [Abstract] [Full Text] [Related]

  • 19. Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis.
    Li KL, Djoukhadar I, Zhu X, Zhao S, Lloyd S, McCabe M, McBain C, Evans DG, Jackson A.
    Neuro Oncol; 2016 Feb 15; 18(2):275-82. PubMed ID: 26311690
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.